News >

Frontline Data for Newly Diagnosed Ovarian Cancer Leave Much to Be Discerned

Caroline Seymour
Published: Thursday, Aug 22, 2019

Jessica L. Berger, MD, a gynecologic oncologist at the University of Pittsburgh Medical Center Hillman Cancer Center

Jessica L. Berger, MD

Before considering intraperitoneal (IP) chemotherapy or dose-dense chemotherapy for a patient with newly diagnosed advanced ovarian cancer, their fitness should be established, said Jessica L. Berger, MD, as both approaches carry more toxicity than that of a standard weekly intravenous (IV) approach.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Publication Bottom Border
Border Publication